Literature DB >> 9239425

Cardiac disease in chronic uremia: pathogenesis.

G M London1, P S Parfrey.   

Abstract

Cardiomyopathy in chronic uremia results from pressure and volume overload. The former causes concentric left ventricular [LV] hypertrophy, results from hypertension and aortic stenosis, and is also associated with diabetes mellitus and anemia. Volume overload causes LV dilatation, results from arteriovenous shunting, salt and water overload, and anemia, and is also associated with ischemic heart disease, hypertension, and hypoalbuminemia. Decreased major arterial compliance and an early return of arterial wave reflections are also associated with the extent of LV hypertrophy. Cardiomyopathy predisposes to diastolic and systolic dysfunction. The latter results from myocyte death, and predisposing factors include ischemic heart disease and the uremic environment. Ischemic heart disease may be atherosclerotic or nonatherosclerotic in origin. Multiple factors contribute to the vascular pathology of chronic uremia, including injury to the vessel wall, dyslipidemia, prothrombotic factors, increased oxidant stress, and hyperhomocysteinemia. Ischemic risk factors include hypertension, LV hypertrophy, hypoalbuminemia, and perhaps hyperparathyroidism. The clinical consequences of cardiomyopathy include heart failure, ischemic heart disease, dialysis hypotension, and arrhythmias. The adverse impact of ischemic heart disease is probably mediated through the development of cardiac failure.

Entities:  

Mesh:

Year:  1997        PMID: 9239425     DOI: 10.1016/s1073-4449(97)70029-3

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  27 in total

Review 1.  Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress.

Authors:  Jiang Liu; Megan N Lilly; Joseph I Shapiro
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

2.  Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis.

Authors:  Lygeri P Soubassi; Theodore C Chiras; Emmanuel D Papadakis; George D Poulos; Dimitrios I Chaniotis; Ioannis P Tsapakidis; Sofia P Soubassi; Stylianos N Zerefos; Nikolaos S Zerefos; Dimitrios A Valis
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 3.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 4.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

5.  Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Authors:  G Boner; M E Cooper; K McCarroll; B M Brenner; D de Zeeuw; P R Kowey; S Shahinfar; T Dickson; R S Crow; H-H Parving
Journal:  Diabetologia       Date:  2005-08-05       Impact factor: 10.122

6.  A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance.

Authors:  Kumudha Ramasubbu; Anita Deswal; Cheryl Herdejurgen; David Aguilar; Adaani E Frost
Journal:  Int J Gen Med       Date:  2010-10-05

7.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

8.  Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging.

Authors:  Rajan K Patel; Scott Oliver; Patrick B Mark; Joanna R Powell; Emily P McQuarrie; James P Traynor; Henry J Dargie; Alan G Jardine
Journal:  Clin J Am Soc Nephrol       Date:  2009-09       Impact factor: 8.237

Review 9.  Diastolic heart failure: a confusing concept.

Authors:  Evert J Dorhout Mees
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

Review 10.  Cardiovascular disease in patients with chronic kidney disease.

Authors:  Julian Wright; Alastair Hutchison
Journal:  Vasc Health Risk Manag       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.